Patent ID: 9555126
Date: 2017-01-31
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of treating CD19+ B-cell malignancies symptom in a human patient in need thereof, said method comprising a) administering to said patient an initial dose of 55 mg/m b) administering to the patient at least 3 subsequent doses of 55 mg/m c) administering to the patient at least 3 further subsequent doses of 55 mg/m a) a heavy chain CDR1 comprising SNWMH (SEQ ID NO.4); a heavy chain CDR2 comprising EIDPSDSYTN (SEQ ID NO.5); and a heavy chain CDR3 comprising GSNPYYYAMDY (SEQ ID NO.6); and b) a light chain CDR1 comprising SASSGVNYMH (SEQ ID NO:1); a light chain CDR2 comprising DTSKLAS (SEQ ID NO:2); and a light chain CDR3 comprising HQRGSYT (SEQ ID NO:3), wherein the maytansinoid is DM4; and wherein the antibody is conjugated to DM4 through N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) linker.